Archives des publications

2015

Avril P, Le Nail LR, Brennan MÁ, Rosset P, De Pinieux G, Layrolle P, Heymann D, Perrot P, Trichet V.Mesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: Potential implications according to the tumor resection status. J Bone Oncol. 2015 Dec 12;5:5-14.
Crémet L, Broquet A, Brulin B, Jacqueline C, Dauvergne S, Brion R, Asehnoune K, Corvec S, Heymann D, Caroff N. Pathogenic potential of Escherichia coli clinical strains from orthopedic implant infections towards human osteoblastic cells. Pathog Dis. 2015;73;73:ftv065.
Arshad MI, Guihard P, Danger Y, Noel G, Le Seyec J, Boutet MA, Richards CD, L'Helgoualc'h A, Genet V, Lucas-Clerc C, Gascan H, Blanchard F, Piquet-Pellorce C, Samson M. Oncostatin M induces IL-33 expression in liver endothelial cells in mice and expands ST2+CD4+ lymphocytes. Am J Physiol Gastrointest Liver Physiol. 2015;309:G542-53.
Bougault C, Briolay A, Boutet MA, Pilet P, Delplace S, Le Goff B, Guicheux J, Blanchard F, Magne D. Wnt5a is expressed in spondyloarthritis and exerts opposite effects on enthesis and bone in murine organ and cell cultures. Transl Res. 2015;166:627-38.
Rabeony H, Pohin M, Vasseur P, Petit-Paris I, Jégou JF, Favot L, Frouin E, Boutet MA, Blanchard F, Togbe D, Ryffel B, Bernard FX, Lecron JC, Morel F. IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome. Eur J Immunol. 2015; 45:2847-57.
Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, Kellokumpu-Lehtinen PL, Lauttia S, Tynninen O, Joensuu H, Heymann D, Määttä JA. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res. 2015.5;17:101.
Gama A, Navet B, Vargas JW, Castaneda B, Lézot F. Bone resorption: an actor of dental and periodontal development? Front Physiol. 2015;6:319.2015.00319. Review.
Quillard T, Araújo HA, Franck G, Shvartz E, Sukhova G, Libby P. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. EurHeart J. 2015;36: 1394-1404.
Smith MJ, Isidor B, Beetz C, Williams SG,Bhaskar SS, Richer W, O'Sullivan J, Anderson B, Daly SB, Urquhart JE, Fryer A,Rustad CF, Mills SJ, Samii A, du Plessis D, Halliday D, Barbarot S, BourdeautF, Newman WG, Evans DG. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology. 201513;84:141-7.
Rieger E, Dupret-Bories A, Salou L, Metz-Boutigue MH, Layrolle P, Debry C, Lavalle P, Engin Vrana N. Controlled implant/soft tissue interaction by nanoscale surface modifications of 3D porous titanium implants. Nanoscale. 2015;21;7: 9908-18.
Lamora A, Mullard M, Amiaud J, Brion R, Heymann D, Redini F, Verrecchia F. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases. Oncotarget. 2015. 10;6:14413-14427.
Tabareau-Delalande F, Collin C, Gomez-Brouchet A, Bouvier C, Decouvelaere AV, de Muret A, Pagès JC, De Pinieux G. Chromosome 12 long arm rearrangement covering MDM2 and RASAL1 is associated with aggressive craniofacial juvenile ossifying fibroma and extracranial psammomatoid fibro-osseous lesions.. Mod Pathol. 2015; 28:48-56.
Salou L, Hoornaert A, Stanovici J, Briand S, Louarn G, Layrolle P. Comparative bone tissue integration of nanostructured and microroughened dental implants.. Nanomedicine. 2015;10:741-51.
Córdova LA, Trichet V, Escriou V, Rosset P, Amiaud J, Battaglia S, Charrier C, Berreur M, Brion R, Gouin F, Layrolle P, Passuti N, Heymann D. Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model.Acta Biomater. 2015;13:150-8
Salou L, Hoornaert A, Louarn G, Layrolle P. Enhanced osseointegration of titanium implants with nanostructured surfaces: An experimental study in rabbits.Acta Biomater. 2015. 1;11:494-502.
Carapito R,Paul N, Untrau M, Le Gentil M, Ott L, Alsaleh G, Jochem P, Radosavljevic M, Le Caignec C, David A, Damier P, Isidor B, Bahram S. A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia. Mov Disord. 2015;30:423-7.
Ben Arush M, Minard-ColinV, Mosseri V, Defachelles AS, Bergeron C, Algret N, Fasola S, André N, Thebaud E, Corradini N, Bernier V, Martelli H, Ranchère D, Orbach D. Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma? Eur J Cancer. 2015; 51:193-201.
Taieb S, Saada-Bouzid E,Tresch E, Ryckewaert T, Bompas E, Italiano A, Guillemet C, Peugniez C,Piperno-Neumann S, Thyss A, Maynou C, Clisant S, Penel N; French Sarcoma Group. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.. Eur J Cancer. 2015; 201551:202-9.
Ségaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D. Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer. 2015 1;137:73-85
Gobin B, Huin MB, Lamoureux F, Ory B, Charrier C, Lanel R, Battaglia S, Redini F, Lezot F, Blanchard F, Heymann D. BYL719, a new -specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.Int J Cancer. 2015; 15;136:784-96
Segaliny AI, Brion R, Mortier E, Maillasson M, Cherel M, Jacques Y, Le Goff B, Heymann D. Syndecan-1 regulates the biological activities of interleukin-34. Biochim Biophys Acta. 2015; 4;1853:1010-1021.
Guihard P, Boutet MA, Brounais-Le Royer B, Gamblin AL, Amiaud J, Renaud A, Berreur M, Rédini F, Heymann D, Layrolle P, Blanchard F. Oncostatin M, an Inflammatory Cytokine Produced by Macrophages, Supports Intramembranous Bone Healing in a Mouse Model of Tibia Injury.. Am J Pathol, 2015.185:765-75
Vergult S, Dheedene A, Meurs A, Faes F, Isidor B, Janssens S, Gautier A, Le Caignec C,Menten B. Genomic aberrations of the CACNA2D1 gene in three patients with epilepsy and intellectual disability. Eur J Hum Genet. 2015;23:628-32.
Carapito R, Isidor B,Guerouaz N, Untrau M, Radosavljevic M, Launay E, Cassagnau E, Frenard C, AubertH, Romefort B, Le Caignec C, Ott L, Paul N, Barbarot S, Bahram S. Homozygous IL36RN mutation and NSD1 duplication in a patient with severe pustular psoriasis and symptoms unrelated to deficiency of interleukin-36 receptor antagonist.. Br J Dermatol.2015;172:302-5.
Knapen M, Gheldof D, Drion P, Layrolle P, Rompen E, Lambert F. Effect of leukocyte- and platelet-rich fibrin (L-PRF) on bone regeneration: a study in rabbits.. Clin Implant Dent Relat Res.2015;17 Suppl 1:e143-52. I
Lézot F, Chesneau J, Navet B, Gobin B, Amiaud J, Choi Y, Yagita H, Castaneda B, Berdal A, Mueller CG, Rédini F, Heymann D. Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid. Bone. 2015;73:51-9.
Baraut J, Farge D,Jean-Louis F, Masse I, Grigore EI, Arruda LC, Lamartine J, Verrecchia F, Michel L.Transforming growth factor- increases interleukin-13 synthesis via GATA-3 transcription factor in T-lymphocytes from patients with systemic sclerosis.. Arthritis Res Ther. 2015 31;17:196
Brennan M, Renaud A,Gamblin AL, D'Arros C; Nedellec S, Trichet V, Layrolle P. 3D cell culture and osteogenic differentiation of human bone marrow stromal cells plated onto jet-sprayed or electrospun micro-fiber scaffolds. Biomedical Materials 2015. 4;10:045019.
Lebouvier A, Poignard A, Cavet M, Amiaud J, Leotot J, Hernigou P, Rahmouni A, Bierling P, Layrolle P, Rouard H, Chevallier N .Development of a simple procedure for the treatment of femoral head osteonecrosis with intra-osseous injection of bone marrow mesenchymal stromal cells: study of their biodistribution in the early time points after injection. Stem Cell Res Ther. 2015.13;6:68
Ségaliny AI, Brion R, Brulin B, Maillasson M, Charrier C, Téletchéa S, Heymann D. IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization. Cytokine. 2015;76:170-81.
Guiho R, Biteau K, Heymann D, Redini F. TRAIL-based therapy in pediatric bone tumors: how to overcome resistance. Future Oncol. 2015;11:535-42.
Pochon C, Martelli H,Mussini C, Pariente D, Heymann MF, Corradini N. Primary Hepatic Ewing Sarcoma With EWS-FLI1 RNA Transcript in a Child.. J Pediatr Hematol Oncol. 2015; 37:411-3.
Saumet L, Deschamps F, Marec-Berard P, Gaspar N, Corradini N, Petit P, Sirvent N, Brugières L. Radiofrequency ablation of metastases from osteosarcoma in patients under 25 years: the SCFE experience.Pediatr Hematol Oncol. 2015;32:41-9.
Beranger GE, Djedaini M, Battaglia S, Roux CH, Scheideler M, Heymann D, Amri EZ, Pisani DF. Oxytocin reverses osteoporosis in a sex-dependent manner. Front Endocrinol (Lausanne). 2015. 19;6:81.
Molin A, Lopez-Cazaux S,Pichon O, Vincent M, Isidor B, Le Caignec C. Patients with isolatedoligo/hypodontia caused by RUNX2 duplication. Am J Med Genet A. 2015;167:1386-90.
Isidor B, David A. Twogirls with short stature, short neck, vertebral anomalies, Sprengel deformityand intellectual disability. Eur J MedGenet. 2015;58:47-50.
Lamoureux F & Rédini F. Blocking clusterin inhibits emergence of resistance tozoledronic acid in osteosarcoma. CancerCell & Microenvironment. doi: 10.14800/ccm.438.

2014

Le Goff B, Singbrant S, Tonkin BA, Martin TJ, Romas E, Sims NA, Walsh NC.Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts. Cytokine. 2014; 68:101-9.

Gouin F, Rochwerger AR, Di Marco A, Rosset P, Bonnevialle P, Fiorenza F,Anract P. Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone.. Eur J Cancer. 2014; 50:2425-31.

Darrieutort-Laffite C, Boutet MA, Chatelais M, Brion R, Blanchard F, Heymann D, Le Goff B. IL-1 and TNF promote monocyte viability through the induction of GM-CSF expression by rheumatoid arthritis synovial fibroblasts.. Mediators Inflamm. 2014: 241840,

Brennan MA, Renaud A, Amiaud J, Rojewski MT, Schrezenmeier H, Heymann D, Trichet V, Layrolle P.Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate. Stem Cell Res Ther. 2014.13;5:114

Mullen CA, Vaughan TJ, Voisin MC, Brennan MA, Layrolle P, McNamara LM. Cell morphology and focal adhesion location alters internal cell stress.J R Soc Interface. 2014;11.pii: 20140885

Lézot F, Chesneau J, Battaglia S, Brion R, Farges JC, Heymann D, Rédini F. Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies.. Bone, 68:146-52

Gamblin AL, Renaud A, Charrier C, Hulin P, Louarn G, Heymann D, Trichet V, Layrolle P.Osteoblastic and osteoclastic differentiation of human mesenchymal stem cells and monocytes in a miniaturized three-dimensional culture with mineral granules. Acta Biomater. 2014 pii: S1742-7061, 00378-X.

Gamblin AL, Brennan MA, Renaud A, Yagita H, Lézot F, Heymann D, Trichet V, Layrolle P. Bone tissue formation with human mesenchymal stem cells and biphasic calcium phosphate ceramics: The local implication of osteoclasts and macrophages.. Biomaterials;35; 9660-7

Davaine JM, Quillard T, Brion R, Lapérine O, Merlini T, Gyyomarch B, Chatelais M, Guilbaud F, Brennan MA, Charrier C, Heymann D, Goueffic Y, Heymann MF.Osteoprotegerin, Pericytes and Bone-Like Vascular Calcification Are Associated with Carotid Plaque Stability.. PLoS One,2014. 26;9:e107642.

Lamoureux F, Baud'huin M, Ory B, Guiho R, Zoubeidi A, Gleave M, Heymanna D, Rédini F.Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Oncotarget. 2014. 15;5:7805-19

Buffet A, Smati S, Mansuy L, Ménara M, Lebras M, Heymann MF, Simian C, Favier J, Murat A, Cariou B, Gimenez-Roqueplo AP. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.J Clin Endocrinol Metab. 2014;99:E369-73.

Gouin F, Paul L, Odri GA, Cartiaux O. Computer-Assisted Planning and Patient-Specific Instruments for Bone Tumor Resection within the Pelvis: A Series of 11 Patients.Sarcoma. 2014:842709
Gouin F, Rochwerger AR, Di Marco A, Rosset P, Bonnevialle P, Fiorenza F, Anract P. Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone. Eur J Cancer. 2014. 50:2425-31

Lamora A, Talbot J, Bougras G, Amiaud J, Leduc M, Chesneau J, Taurelle J, Stresing V, Le Deley MC, Heymann MF, Heymann D, Redini F, Verrecchia F. Overexpression of Smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma.Clin Cancer Res. 2014. 20:5097-112.

Miot-Noirault E, Vidal A, Morlieras J, Bonazza P, Auzeloux P, Besse S, Dauplat MM, Peyrode C, Degoul F, Billotey C, Lux F, Rédini F, Tillement O, Chezal JM, Kryza D, Janier M.Small rigid platforms functionalization with quaternary ammonium: Targeting extracellular matrix of chondrosarcoma. Nanomedicine. 2014. S1549-96300324-4.

Tabareau-Delalande F, Collin C, Gomez-Brouchet A, Bouvier C, Decouvelaere AV, de Muret A, Pagès JC, de Pinieux G. Chromosome 12 long arm rearrangement covering MDM2 and RASAL1 is associated with aggressive craniofacial juvenile ossifying fibroma and extracranial psammomatoid fibro-osseous lesions.Mod Pathol. 2014 sous presse

Gobin B, Baud'huin M, Lamoureux F, Ory B, Charrier C, Lanel R, Battaglia S, Redini F, Lezot F, Blanchard F, Heymann D.BYL719, a new -specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. . Int J Cancer, sous presse.

Nollet M, Santucci-Darmanin S, Breuil V, Al-Sahlanee R, Cros C, Topi M, Momier D, Samson M, Pagnotta S, Cailleteau L, Battaglia S, Farlay D, Dacquin R, Barois N, Jurdic P, Boivin G, Heymann D, Lafont F, Lu SS Dempster D, Carle GF, Pierrefite-Carle V. Autophagy in osteoblasts is involved in mineralization and bone homeostasis.. Autophagy 2014 , sous presse.

Rice GI, Del Toro Duany Y, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G, Bader-Meunier B, Baildam EM, Battini R, Beresford MW, Casarano M, Chouchane M, Cimaz R, Collins AE, Cordeiro NJ, Dale RC, Davidson JE, De Waele L, Desguerre I, Faivre L, Fazzi E, Isidor B, Lagae L, Latchman AR, Lebon P, Li C, Livingston JH, Lourenço CM, Mancardi MM, Masurel-Paulet A, McInnes IB, Menezes MP, Mignot C, O'Sullivan J, Orcesi S, Picco PP, Riva E, Robinson RA, Rodriguez D, Salvatici E, Scott C, Szybowska M, Tolmie JL, Vanderver A, Vanhulle C, Vieira JP, Webb K, Whitney RN, Williams SG, Wolfe LA, Zuberi SM, Hur S, Crow YJ.Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling.Nat Genet. 2014. sous presse
Davison NL, Gamblin AL, Layrolle P, Yuan H, de Bruijn JD, Barrère-de Groot F. Liposomal clodronate inhibition of osteoclastogenesis and osteoinduction by submicrostructured beta-tricalcium phosphate. Biomaterials. 2014;35:5088-97.

Lamoureux F, Baud'huin1 M, Rodriguez Calleja1 L, Jacques C, Berreur M, Redini F, Lecanda F, Bradner JE, Heymann D, Ory B.Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle.. Nature Commun. 2014, 19;5:3511.

Rosset P, Deschaseaux F, Layrolle P.Cell therapy for bone repair. Orthop Traumatol Surg Res. 2014;100:S107-S112.

Odri G, Kim PP, Lamoureux F, Charrier C, Battaglia S, Amiaud J, Heymann D, Gouin F, Rédini F. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration. BMC Cancer, 2014,10;14:169.

Gobin B, Moriceau G, Ory B, Charrier C, Brion R, Blanchard F, Rédini F, Heymann D. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.. PLoS ONE,2014;9:e90795.

Gobin B, Battaglia S, Lanel R, Chesneau J, Amiaud J, Redini F, Ory B, *Heymann D. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate.*Cancer Letters;2014;344:291-8

Lau A, Sun J, Hannah W, Livingston E, Heymann D, Bateman T, Monahan P. Joint bleeding in factor VIII deficient mice causes an acute loss of trabecular bone and calcification of joint soft tissues which is prevented with aggressive factor replacement. Haemophilia, 2014;20:716-22

Cordova Jara L, Stresing V, Gobin B, Rosset P, Passuti N, Gouin F, Layrolle P, Trichet V, Heymann D.Orthopaedic implant failure: aseptic implant loosening-the contribution and future challenges of mouse models in translational research.. Clinical Science, 2014; 1;127:277-93

Beranger GE, Pisani DF, Castel J, Djedaini M, Battaglia S, Amiaud J, Boukhechba F, Ailhaud G, Michiels JF, Heymann D, Luquet S, Amri EZ.Oxytocin reverses ovariectomy-induced osteopenia and body fat gain. Endocrinology. 2014:20131688.

Téletchéa S, Stresing V, Hervouet S, Baud'huin M, Heymann MF, Bertho G, Charrier C, Ando K, Heymann D.Novel RANK Antagonists for the Treatment of Bone Resorptive Disease: Theoretical Predictions and Experimental Validation.J Bone Miner Res. 2014 Jan 6. doi: 10.1002/jbmr.2170

2013

Tabareau-Delalande F, Collin C, Gomez-Bouchet A, Decouvelaere AV, Bouvier C, Larousserie F, Marie B, Delfour C, Aubert S, Rosset P, de Muret A, Pages JC, de Pinieux G. Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions. Mod. Pathol 2013;26:911-21.

Carapito R, Paul N, Untrau M, Ott L, Corradini N, Poignant S, Geffroy^ L, Caldagues^ E, Heymann MF, Cassagnau E, Isidor B, Bahram S.A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.. *J Human Genet,2013;14. doi: 10.1038/jhg.118

Castaneda B, Simon Y, Ferbus D, Robert B, Chesneau J, Mueller CG, Berdal A, Lézot F.Role of RANKL (TNFSF11)-Dependent Osteopetrosis in the Dental Phenotype of Msx2 Null Mutant Mice..Plosone 2013. 21;8:e80054. doi: 10.1371

Gouin F, Dumaine V; the French Sarcoma and Bone Tumor Study Groups (GSF-GETO).Local recurrence after curettage treatment of giant cell tumors in peripheral bones: Retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Groups).Orthop Traumatol Surg Res. 2013. Oct;99(6 Suppl):S313-8

Gouëffic Y, Davaine JM, Merlini T, Rimbert A, Hérisson F, Heymann MF, Heymann D, Steenman M, Lambert G.[Arterial heterogeneity]. Rev Med Interne. 2013;34:61-5.
Davaine JM, Quérat J, Guyomarch B, Brennan MÁ, Costargent A, Chaillou P, Patra P, Gouëffic Y.Incidence and the Clinical Impact of Stent Fractures after Primary Stenting for TASC C and D Femoropopliteal Lesions at 1 Year. Eur J Vasc Endovasc Surg. 2013;46:201-12.

Brennan MA, Davaine JM, Layrolle P.Pre-vascularization of bone tissue-engineered constructs. Stem Cell Res Ther. 2013. 14;4:96.

Isidor B, Geffroy L, De Courtivron B, Le Caignec C, T Thiel C, Mortier G, Cormier-Daire V, David A, Toutain A. A new form of severe spondyloepimetaphyseal dysplasia: Clinical and radiological characterization.. American Journal of Medical Genetics. 2013.doi: 10.1002/ajmg.a.36132.

Odri GA, Padiolleau GB, Gouin FT.Oversized Cups as a Major Risk Factor of Postoperative Pain After Total Hip Arthroplasty.J Arthroplasty. 2013. doi:pii: S0883-5403:00503-2.

Monderer D, Luseau A, Bellec A, David E, Ponsolle S, Saiagh S, Bercegeay S, Piloquet P, Denis D, Lodé L, Rédini F, Biger M, Heymann D, Heymann MF, Le Bot R, Gouin F, Blanchard F. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.. Lab Invest, 2013;93:1100-14.

Berthelot JM, Le Goff B, Maugars Y.Pathogenesis of hyperostosis: A key role for mesenchymatous cells? Joint Bone Spine. 2013 May 31. doi:pii: S1297-319X:00089-4. 10.1016

Savoie A, Gouin F, Maugars Y, Isidor B, Larrose C, Berthelot JM. Treatment responses in five patients with ribbing disease including two with 466C>T missense mutations in TGF1.Joint Bone Spine. 2013. doi:pii: S1297-319X:00027-4.

Rédini F, Odri G, Picarda G, Gaspar N, Heymann MF, Corradini N, Heymann D. Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma? Expert Opin Emerg Drugs,2013 18:339-52.

Picarda G, Matous E, Amiaud J, Charrier C, Lamoureux f, Heymann MF, Tirode F, Pitard B, Trichet V, Heymann D, F Redini. Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoima by inhibiting RANKL. J Bone Oncol, 2013;doi:10.1016/j.jbo.2013.04.004

Heymann D, Rédini F. Targeted therapies for bone sarcomas. BoneKey Reports sous presse

Rousseau J, Gioia R, Layrolle P, Lieubeau B, Heymann D, Rossi A, Marini JC, Trichet V, Forlino A. Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta.. Eur J Human Genet, 2013.doi: 10.1038/ejhg.

Isidor B, Le Meur G, Conti C, Caldagues E, Lainey E, Launay E, Leclair MD, Le Francois T, Pichon O, Boisseau P, Migraine A, Keren B, Caignec CL, Crow YJ, David A.Exudative retinopathy, cerebral calcifications, duodenal atresia, preaxial polydactyly, micropenis, microcephaly and short stature: A new syndrome?Am J Med Genet A. 2013 Jul 3. doi: 10.1002/ajmg.a.36021
Baud'huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, Redini F, Heymann MF, Heymann D.Osteoprotegerin: Multiple partners for multiple functions.Cytokine Growth Factor Rev. 2013 Jul 1. doi:pii: S1359-6101:00059-2. 10.1016/j.cytogfr.2013.06.001

Le Goff B, Berthelot JM, Maugars Y, Heymann D.Osteoclasts in RA: Diverse origins and functions.Joint Bone Spine. 2013;80:586-91. doi: 10.1016/j.jbspin.2013.04.002.

Miot-Noirault E, David E, Vidal A, Besse S, Dauplat MM, Gouin F, Heymann D, Rédini F. 99mTc-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model. European Journal of Nuclear Medicine and Molecular Imaging Research, 2013;20;3:40. doi: 10.1186/2191-219X-3-40.

Ando K, Heymann MF, Stresing V, Mori K, Rédini F, Heymann D.Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 2013; 24;5:591-616. doi: 10.3390/cancers5020591.

Deschaseaux F, Gaillard J, Langonné A, Chauveau C, Naji A, Bouacida A, Rosset P, Heymann D, De Pinieux G, Rouas-Freiss N, Sensébé L. Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue. FASEB J. 2013;27:2977-87

Georges S, Chesneau J, Hervouet S, Taurelle J, Gouin F, Redini F, Padrines M, Heymann D, Fortun Y, Verrecchia F.A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis.Eur J Cancer. 2013 doi:pii: S0959-8049:00150-0. 10.1016/j.ejca.2013.02.020.

Benslimane-Ahmim Z, Poirier F, Delomenie C, Lokajczyk A, Grelac F, Galy-Fauroux I, Mohamedi A, Fischer AM, Heymann D, Lutomski D, Boisson-Vidal C.Mechanistic study of the proangiogenic effect of osteoprotegerin.Angiogenesis. 2013,16:575-93.

Milan JL, Lavenus S, Pilet P, Louarn G, Wendling S, Heymann D, Layrolle P, Chabrand P. Computational model combined with in vitro experiments to analyse mechanotransduction during mesenchymal stem cell adhesion. Eur Cell Mater. 2013;16;25:97-113.
Lionetto S, Little A, Moriceau G, Heymann D, Decurtins M, Plecko M, Filgueira L, Cadosch D.Pharmacological blocking of the osteoclastic biocorrosion of surgical stainless steel in vitro.J Biomed Mater Res A.2013, 101:991-997

Talbot J, Brion R, Picarda G, Amiaud J, Chesneau J, Bougras G, Stresing V, Tirode F, Heymann D, Redini F, Verrecchia FLoss of connexin43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated bone osteolysis. BBA - Molecular Basis of Disease.2013;1832:553-64

Odri GA, Revert R, Deschamps C, Romih M, Maugars Y, Heymann D, Delecrin J.Effect of adding bone marrow to ceramic graft materials with different interconnectivities in lumbar arthrodesis : Quantification of bone formation.J Orthop Sci. 2013,18:321-330

2012

Bussone G, Tamby MC, Calzas C, Kherbeck N, Sahbatou Y, Sanson C, Ghazal K, Dib H, Weksler BB, Broussard C, Verrecchia F, Yaici A, Witko-Sarsat V, Simonneau G, Guillevin L, Humbert M, Mouthon L. IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis. 2012;71:596-605.

Berthelot JM, De Bandt M, Morel J, Benatig F, Constantin A, Gaudin P, Le Loet X, Maillefert JF, Meyer O, Pham T, Saraux A, Solau-Gervais E, Spitz E, Wendling D, Fautrel B, Guillemin F, STPR group of French Society of Rheumatology;A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: the 'FLARE' instrument. Ann Rheum Dis. 2012;71:1110-6.

Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Van Glabbeke M, Debiec-Rychter M, Emile JF, Duffaud F, Martin-Broto J, Landi B, Adenis A, Bertucci F, Bompas E, Bouché O, Leyvraz S, Judson I, Verweij J, Casali P, BlayJY, Hohenberger P; European Organisation for Research and Treatment of Cancer. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumours in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012; 15;18:4458-64.

Guihard P, Danger Y, Brounais B, David E, Brion R, Delecrin J, Richards CD, Chevalier S, Rédini F, Heymann D, Gascan H, Blanchard F. Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling. Stem Cells. 2012;30:762-72.

Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C, Defachelles AS, André N, Corradini N, Schmitt C, Tabone MD, Blouin P, Sirvent N, Goma G, Geoerger B, Oberlin O. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma - A report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE). Eur J Cancer. 2012; 48:2409-16.

Geoerger B, Estlin EJ, Aerts I, Kearns P, Gibson B, Corradini N, Doz F, Lardelli P, Miguel BD, Soto A, Prados R, Vassal G. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study. Eur J Cancer. 2012; 48:289-96.

Trichet V, Layrolle P, Escriou V. Lipid nanoparticles for siRNA delivery in lungs. Nanomedicine (Lond). 2012 Feb;7:181-3.

Lavenus S, Trichet V, Le Chevalier S, Hoornaert A, Louarn G, Layrolle P. Cell differentiation and osseointegration influenced by nanoscale anodized titanium surfaces. Nanomedicine. 2012;7:967-8.

Hess E, Duheron V, Decossas M, Lézot F, Berdal A, Chea S, Golub R, Bosisio MR, Bridal SL, Choi Y, Yagita H, Mueller CG.RANKL induces organised lymph node growth by stromal cell proliferation. JImmunol.2012;188:1245-54.

Pautier P, Floquet A, Penel N, Piperno-Neumann S, Isambert N, Rey A, Bompas E, Cioffi A, Delcambre C, Cupissol D, Collin F, Blay JY, Jimenez M, Duffaud F. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer(FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 2012;17:1213-20.

Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreau C, Bay JO, Bousquet G, Piperno-Neumann S, Isambert N, Lemaitre L, Fournier C, Gauthier E, Collard O, Cupissol D, Clisant S, Blay JY, Penel N; French Sarcoma Group (GSF/GETO). Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012; 17:260-6.

David E, Tirode F, Baud'Huin M, Guihard P, Laud K, Delattre O, Heymann MF, Heymann D, Rédini F, Blanchard F. Oncostatin M Is a Growth Factor for Ewing Sarcoma. Am J Pathol.2012;181:1782-95.

Picarda G, Surget S, Guiho R, Télétchéa S, Berreur M, Tirode F, Pellat-Deceunynck C, Heymann D, Trichet V, Rédini F. A functional, new short isoform of Death Receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms. Mol Cancer Res. 2012;10:336-46.

Delaplace M, Lhommet C, De Pinieux G, Vergier B, de Muret A, Machet L. Primary cutaneous Ewing sarcoma: a systematic review focused on treatment and outcome. Br J Dermatol.2012;166:721-6.

Picarda G, Trichet V, Télétchéa S, Heymann D, Rédini F.TRAIL receptor signaling and therapeutic option in bone tumours: the trap of the bone microenvironment. Am J CancerRes. 2012;45-64.

Italiano A, Cioffi A, Coco P, Maki RG, Schöffski P, Rutkowski P, Le Cesne A, Duffaud F, Adenis A, Isambert N, Bompas E, Blay JY, Casali P, Keohan ML, Toulmonde M, Antonescu CR, Debiec-Rychter M, Coindre JM, Bui B. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumours (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol. 2012; 19:1551-9.

Vuillaumier-Barrot S, Isidor B, Dupré T, Le Bizec C, David A, Seta N. Expanding the Spectrum of PMM2-CDG Phenotype. JIMD Rep. 2012;5:123-5.

Pichard V, Aubert D, Boni S, Battaglia S, Ivacik D, Nguyen TH, Arbuthnot P, Ferry N. Specific micro RNA-regulated TetR-KRAB transcriptional control of transgene expression in viral vector-transduced cells. PLoS One. 2012; 7 :e51952.

Guyader C, Céraline J, Gravier E, Morin A, Michel S, Erdmann E, de Pinieux G, Cabon F, Bergerat JP, Poupon MF, Oudard S. Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced bytyrosine kinase inhibitors. PLoS One 2012;7:e42252.

Brullé L, Vandamme M, Riès D, Martel E, Robert E, Lerondel S, Trichet V, Richard S, Pouvesle JM, Le Pape A. Effects of a Non Thermal Plasma Treatment Alone or in Combination with Gemcitabine in a MIA PaCa2-luc Orthotopic Pancreatic Carcinoma Model. PLoS One. 2012;7:e52653.

Bouacida A, Rosset P, Trichet V, Guilloton F, Espagnolle N, Cordonier T, Heymann D, Layrolle P, Sensébé L, Deschaseaux F. Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells. PLoS One.2012;7:e48648.

Guillard C, Lintz F, Odri GA, Vogeli D, Colin F, Collon S, Chappard D, Gouin F, Robert H. Effects of graft pretensioning in anterior cruciate ligament reconstruction. Knee Surg Sports Traumatol Arthrosc. 2012; 20:2208-13.

suite 2012

Peyrode C, Weber V, David E, Vidal A, Auzeloux P, Communal Y, Dauplat MM, Besse S, Gouin F, Heymann D, Chezal JM, Rédini F, Miot-Noirault E. Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies. Invest New Drugs. 2012; 30:178-90.

Lopes R, Philippeau JM, Passuti N, Gouin F. High rate of ceramic sandwich iner fracture. Clin Orthop Relat Res. 2012;470:1705-10.

Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Rédini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R. The first European interdisciplinary ewing sarcoma research summit. Front Oncol. 2012;2:54.

Heymann MF, Herisson F, Davaine JM, Charrier C, Battaglia S, Passuti N, Lambert G, Gouëffic Y, Heymann D. Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: Comparison between carotid and femoral beds. Cytokine. 2012;58:300-6. review

Couec ML, André N, Thebaud E, Minckes O, Rialland X, Corradini N, Aerts I, Bérard PM, Bourdeaut F, Leblond P; on the behalf of the Comité Pharmacologie of the SFCE. Bevacizumab and irinotecan in children with recurrent or refractory brain tumours: Toxicity and efficacy trends. Pediatr Blood Cancer. 2012; 15;59:34-8.

Schmitt F, Caldari D, Corradini N, Gicquel P, Lutz P, Leclair MD, Podevin G. Tolerance and efficacy of preventive gastrostomy feeding in pediatric oncology. Pediatr Blood Cancer.2012; 59:874-80.

Bertoncini P, Le Chevalier S, Lavenus S, Layrolle P, Louarn G. Early adhesion of human mesenchymal stem cells on TiO(2) surfaces studied by single-cell force spectroscopy measurements. J Mol Recognit. 2012;25:262-9.

Bienvenu T, Diebold B, Chelly J, Isidor B. Refining the phenotype associated with MEF2C point mutations. Neurogenetics. 2013;14:71-5.

Isidor B, Poignant S, Picherot G, Mégabarné A, Quartier P, Bader-Meunier B, Le Caignec C, Le Merrer M, Baujat G, Cormier-Daire V, David A. Progressive polyepiphyseal dysplasia with arthropathy: a distinct disorder from idiopathic juvenile arthritis and pseudorheumatoid dysplasia? Am J Med Genet A. 2012;158A:1754-8.

Isidor B, Villa O, Pichon O, Briand A, Poulain D, Boisseau P, Pérez-Jurado LA, Le Caignec C. De novo duplication and deletions at 7q in a three-generation family. Am J Med Genet A. 2012;158A:1493-7.

Strullu M, Rialland F, Cahu X, Brissot E, Corradini N, Thomas C, Blin N, Rialland X, Méchinaud F, Mohty M. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience. Eur J Haematol. 2012; 88:504-9.

Miot-Noirault E, Gouin F, Dauplat MM, Heymann D, Chezal JM, Rédini F. Relevance of the POS-1 Orthotopic Model As An "Imaging Model" for In Vivo and Simultaneous Monitoring of Tumour Proliferation and Bone Remodeling in Osteosarcoma. Cancer Biother Radiopharm. 2012;27:96-103.

Eugene T, Corradini N, Carlier T, Dupas B, Leux C, Bodet-Milin C. F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas. Nucl Med Commun. 2012; 33:1089-95.

Atean I, Pointreau Y, Rosset P, Garaud P, De-Pinieux G, Calais G. Prognostic factors of extremity soft tissue sarcoma in adults. A single institution alanalysis. Cancer Radiother. 2012;16:661-6.

Lintz F, Moreau A, Odri GA, Waast D, Maillard O, Gouin F. Critical study of resection margins in adult soft-tissue sarcoma surgery. Orthop Traumatol Surg Res. 2012;98:S9-S18

Bouguennec N, Gouin F, Piétu G. Isolated anterior unilateral sacroiliac dislocation without pubic arch disjunction. Orthop Traumatol Surg Res. 2012;98:359-62.

Colin F, Lintz F, Bargoin K, Guillard C, Venet G, Tesson A, Gouin F. Aseptic arthritis after ACL reconstruction by Tape Locking Screw (TLS®): report of two cases. Orthop Traumatol Surg Res.2012;98:363-5.

Baraut J, Farge D, Jean-Louis F, Kesmandt H, Durant C, Verrecchia F, Michel L. [Cytokines in systemic sclerosis]. Pathol Biol (Paris). 2012;60:127-39.

Lejus C, Desdoits A, Lambert C, Langlois C, Roquilly A, Gouin F, Asehnoune K. Preoperative moderate renal impairment is an independent risk factor of transfusion in elderly patients undergoing hip fracture surgery and receiving glow-molecular-weight heparin for thromboprophylaxis. J Clin Anesth. 2012; 24:378-84.

Demoor-Goldschmidt C, Minard-Colin V, Cassagneau E, Supiot S, Oberlin O, D'hautuille C, Corradini N. Ameloblastic Fibrosarcoma of the Mandible: Report of 2 Chemosensitive Pediatric Cases.J Pediatr Hematol Oncol. 2012; 34:72-6.

Geffroy L, Hamel O, Odri GA, Guillard S, Passuti N, Gouin F, Rogez JM, Hamel A. Treatment of an aneurysmal bone cyst of the lumbar spine in children and teenagers, about five cases. J Pediatr Orthop B. 2012;21:269-75.

Cormier B, Arbion F, Rousselot C, Gaillardin L, de Pinieux G. About a case of rhabdomyosarcoma with an aberrant expression of epithelial markers: a cause ofmisdiagnosis. Ann Pathol. 2012;32:224-8.

Illac C, Delisle MB, Bonnevialle P, Chiavassa-Gandois H, de Pinieux G, Gomez-Brouchet A. Telangiectatic osteosarcoma secondary to a liposclerosingmyxofibrous tumour: a case report. Ann Pathol.2012;32:259-62.

Gaspar N, Di Giannatale A, Geoerger B, Rédini F, Corradini N, Enz-Werle N, Tirode F, Marec-Berard P, Gentet JC, Laurence V, Piperno-Neumann S, Oberlin O, Brugieres L. Bone sarcomas: from biology to targeted therapies. Sarcoma. 2012;2012:301975 review

Duffaud F, Even C, Ray-Coquard I, Bompas E, Khoa-Huynh T, Salas S, Cassier P, Dufresne A, Bonvalot S, Ducimetiere F, Le Cesne A, Blay JY. Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients. Clin Sarcoma Res. 2012; 5;2:11

Talbot J, Verrecchia F.[Gap junctions and bone remodeling].Biol Aujourdhui. 2012;206:125-34.

Publications 2010- 2011-2009

Publications 2008 - 2000

Mis à jour le 11 février 2019 par Sandrine BARTLETT.